Skip Navigation

Publication Detail

Title: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.

Authors: Ascierto, Paolo Antonio; Fox, Bernard A; Urba, Walter J; Anderson, Ana Carrizosa; Atkins, Michael B; Borden, Ernest C; Brahmer, Julie R; Butterfield, Lisa H; Cesano, Alessandra; Chen, Daniel C; de Gruijl, Tanja D; Dillman, Robert O; Drake, Charles G; Emens, Leisha A; Gajewski, Thomas F; Gulley, James L; Stephen Hodi, F Jr; Hwu, Patrick; Kaufman, David; Kaufman, Howard L; Lotze, Michael T; McNeel, Douglas G; Margolin, Kim M; Marincola, Francesco M; Mastrangelo, Michael J; Maus, Marcela V; Parkinson, David R; Romero, Pedro J; Sondel, Paul M; Spranger, Stefani; Sznol, Mario; Weiner, George J; Wigginton, Jon M; Weber, Jeffrey S

Published In J Immunother Cancer, (2020 Apr)

Abstract: Abstract not available from PubMed.

PubMed ID: 32300051 Exiting the NIEHS site

MeSH Terms: Betacoronavirus; COVID-19; Coronavirus Infections/diagnostic imaging; Coronavirus Infections/drug therapy; Coronavirus Infections/immunology*; Coronavirus Infections/therapy*; Drug Approval; Humans; Immunologic Factors/therapeutic use*; Immunotherapy*; Inflammation/blood; Inflammation/therapy; Interleukin-6/agonists; Neoplasms/therapy; Pandemics; Pneumonia, Viral/diagnostic imaging; Pneumonia, Viral/drug therapy; Pneumonia, Viral/immunology*; Pneumonia, Viral/therapy*; Receptors, Interleukin-6/agonists; SARS-CoV-2

Back
to Top